ARDX
ARDELYX, INC.
Key Financials
Gross Profit
$4.7M
↑ 108.0%
Operating Income
$-40977000
↓ 46.6%
Net Income
$-61599000
↓ 57.4%
Revenue
$407.3M
↑ 22.1%
EPS (Diluted)
$-0.26
↓ 52.9%
Total Assets
$501.6M
↑ 15.1%
Total Liabilities
$334.7M
↑ 27.5%
Long-term Debt
$202.8M
↑ 34.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 144 | 8/21/2026 | View on SEC |
| 144 | 8/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ARDX |
| Company Name | ARDELYX, INC. |
| CIK | 1437402 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 510-745-7047 |